Drug Discovery and Clinic

DDC aims the pharmaceutical development of Dihydroorotate Dehydrogenase inhibitors and has the goal of bringing its best molecule to the clinical stage within 1 or 2 years. It is a potential new drug for the treatment of Acute Myeloid Leukemia (AML) that could significantly improve patient’s survival over 5 years.